// COMPANY
Soufflé Therapeutics
SECTOR BIOTECHMENTIONS 1LAST SEEN OCTOBER 15, 2026
Discussed in
// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
funding·StrictlyVC·OCTOBER 15, 2026
“Soufflé Therapeutics... develops RNA therapies that target specific cells outside the liver to treat muscle diseases, heart failure, and metabolic disorders... raised a $135M Series B.”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.